Publications by authors named "C de Chillou"
Background: Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tachycardia. Whether catheter ablation is more effective than antiarrhythmic drugs as a first-line therapy in patients with ventricular tachycardia is uncertain.
View Article and Find Full Text PDFArticle Synopsis
- Robotic magnetic navigation (RMN)-guided catheter ablation (CA) technology has been effectively used for nearly 20 years in treating heart rhythm disorders, showing benefits like greater catheter stability and safety.
- This consensus paper aims to compile current knowledge and offer guidelines on utilizing RMN-guided CA for conditions like atrial fibrillation (AF) and ventricular arrhythmias (VA).
- The expert group reviewed literature and shared experiences to create a structured set of recommendations, addressing practical aspects of RMN use in clinical settings for optimal patient care.
Article Synopsis
- This study looks at how well doctors can predict sudden cardiac death after someone has a heart attack using a measurement called left ventricular ejection fraction (LVEF).
- They combined information from over 140,000 heart attack patients to see if LVEF alone is good enough for deciding who should get a heart device called a defibrillator.
- The results showed that LVEF didn't do a great job at predicting sudden cardiac death, which means doctors need better ways to tell who is at risk.
Background And Aims: Prophylactic implantable cardioverter-defibrillators (ICDs) are not recommended until left ventricular ejection fraction (LVEF) has been reassessed 40 to 90 days after an acute myocardial infarction. In the current therapeutic era, the prognosis of sustained ventricular arrhythmias (VAs) occurring during this early post-infarction phase (i.e.
View Article and Find Full Text PDFStereotactic arrythmia radioablation (STAR) is a novel, non-invasive and promising treatment option for ventricular arrythmias (VA). It has been applied in highly selected patients mainly as bail-out procedure, when (multiple) catheter-ablations, together with anti-arrhythmic drugs, were unable to control the VAs. Despite the increasing clinical use there is still limited knowledge of the acute and long-term response of normal and diseased myocardium to STAR.
View Article and Find Full Text PDF